Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 9/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6045621 | 0.98 | OPRM1 (0.49) | OPRM1CHRM2CHRM3OPRD1OPRK1 | |
| SCHEMBL6045484 | 0.88 | OPRM1 (0.56) | OPRM1CHRM2CHRM3OPRD1OPRK1 | |
| Oxalic Acid SCHEMBL6045513 | 0.80 | OPRM1 (0.56) | OPRM1OPRD1OPRK1ALDH1A1 | |
| Oxalic Acid SCHEMBL6045761 | 0.80 | OPRM1 (0.67) | OPRM1OPRD1OPRK1 | |
| Oxalic Acid SCHEMBL6045583 | 0.78 | OPRM1 (0.56) | OPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL6045500 | 0.77 | OPRM1 (0.69) | OPRM1OPRD1OPRK1 | |
| SCHEMBL6045487 | 0.77 | OPRM1 (0.58) | OPRM1OPRD1OPRK1KDM4EALDH1A1 | |
| Oxalic Acid SCHEMBL19178214 | 0.77 | OPRM1 (0.61) | OPRM1OPRD1OPRK1 | |
| SCHEMBL2990423 | 0.77 | OPRM1 (0.58) | OPRM1OPRD1OPRK1ALDH1A1 | |
| Oxalic Acid SCHEMBL6045548 | 0.76 | OPRM1 (0.55) | OPRM1OPRD1OPRK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-09 | — | — | US | disclosed |
| EP-1559428-A1 | RECEPTOR REGULATOR | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252797-A1 | Receptor regulator | NMUR1, NMUR2, NMBR | OPRM1 148/4885CHRM2 630/4885CHRM3 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.